Lipitor Diabetes Lawsuit News: Federal Bellwether Trial to Begin on January 13th, Bernstein Liebhard LLP Reports

October 7, 2015 - Lipitor diabetes lawsuits (http://www.lipitorlawsuitcenter.com/) continue to move forward in a federal multidistrict litigation currently underway in the U.S. District Court, District of South Carolina. According to a notice posted on the Court's website on September 28th, the proceeding's first bellwether trial is scheduled to begin on January 13, 2016. The Court has also directed the parties to submit an amended pretrial schedule by October 16, 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

"Our Firm is representing Lipitor lawsuit plaintiffs in this litigation, and we are pleased to see these cases progressing," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to provide free and confidential case reviews to individuals who may have been harmed by Lipitor.

Lipitor Litigation
Court records indicate that more than 2,500 Lipitor diabetes claims are currently pending in the multidistrict litigation underway in South Carolina. Bellwether trials are an important part of any multidistrict litigation, as the outcomes of such cases may provide insight into how juries could decide similar lawsuits. The case chosen for the proceeding's first bellwether trial was filed on behalf of a now 67-year-old woman who began taking the statin medication in 1997. Prior to the initiation of treatment, the plaintiff says she was healthy and of a normal weight. She alleges that Lipitor caused her Type 2 diabetes, and claims that Pfizer, Inc. failed to adequately warn doctors and patients about this risk.

The Lipitor diabetes litigation has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) required all statin manufacturers to update their product labels with information regarding the medication's potential to effect blood glucose levels. Plaintiffs assert that the modifications made to the Lipitor label in response to that mandate still do not adequately warn patients about this potential complication.

Lipitor patients who allegedly developed Type 2 diabetes due to their use of the statin medication may be entitled to compensation. To learn more about the federal Lipitor diabetes litigation, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to obtain a free legal review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.lipitorlawsuitcenter.com/